LBA
NAMS icon

Letko, Brosseau & Associates’s NewAmsterdam Pharma NAMS Stock Holding History

Letko, Brosseau & Associates’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Hold
11,775
– – 0.01% 82
2025
Q4 		$413K Hold
11,775
– – 0.01% 79
2025
Q3 		$335K Hold
11,775
– – 0.01% 81
2025
Q2 		$213K Buy
+11,775
New +$215K ﹤0.01% 87

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Letko, Brosseau & Associates's NAMS Position: Q1 2026 in Review

Letko, Brosseau & Associates held its NewAmsterdam Pharma (NAMS) position steady in Q1 2026 at 11,775 shares worth $377K. The position accounts for 0.01% of the portfolio, ranked #82.

Letko, Brosseau & Associates first reported a position in NAMS in Q2 2025 and has held it in 4 quarters since. The position peaked at $413K in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Letko, Brosseau & Associates held 11,775 shares of NewAmsterdam Pharma worth $377K as of Q1 2026.
  • Letko, Brosseau & Associates left its NewAmsterdam Pharma share count unchanged in Q1 2026.
  • NewAmsterdam Pharma made up 0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #82 holding.
  • Letko, Brosseau & Associates first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 4 quarters since.
  • Letko, Brosseau & Associates's NewAmsterdam Pharma position peaked at $413K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.